| Confirmed Plenary Speakers (to Date) |
| QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases |
Dr Atwood CHEUNG
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States) |
| The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis |
Dr Andrew DILGER
(BRISTOL-MYERS SQUIBB, Princeton, United States) |
| First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases
|
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany) |
| Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other |
Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations |
Dr Wooseok HAN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South) |
| Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH |
Dr Naoyoshi NOGUCHI
(SCOHIA PHARMA, INC., Fujisawa, Japan) |
| Discovery of AZD8154, a Dual PI3Kγδ Inhibitor, as an Inhaled Treatment for Asthma |
Dr Matthew W. D. PERRY
(ASTRAZENECA, Gothenburg, Sweden) |
| Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy |
Dr Norbert SCHMEES
(BAYER PHARMACEUTICALS, Berlin, Germany) |
| GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH) |
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden) |
| Confirmed Speakers |
|
| Monday 07/09/2020 |
| EFMC-ISMC Virtual Event 2020 - Day 1 |
|
| 17:00 | Opening Address by EFMC President |
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 17:10 | Session Chair |
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland) |
| 17:15 | Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy |
Dr Norbert SCHMEES
(BAYER PHARMACEUTICALS, Berlin, Germany) |
| 17:45 | Discovery of AZD8154, a Dual PI3Kγδ Inhibitor, as an Inhaled Treatment for Asthma |
Dr Matthew W. D. PERRY
(ASTRAZENECA, Gothenburg, Sweden) |
| 18:15 | The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis |
Dr Andrew DILGER
(BRISTOL-MYERS SQUIBB, Princeton, United States) |
| 18:45 | QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases |
Dr Atwood CHEUNG
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States) |
| 19:15 | Closing Remarks |
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland) |
| 19:20 | End of Day 1 |
|
| Tuesday 08/09/2020 |
| EFMC-ISMC Virtual Event 2020 - Day 2 |
|
| 16:00 | Opening Address by EFMC-ISMC Chairman |
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland) |
| 16:10 | Session Chair |
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 16:15 | Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH |
Dr Naoyoshi NOGUCHI
(SCOHIA PHARMA, INC., Fujisawa, Japan) |
| 16:45 | The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations |
Dr Wooseok HAN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South) |
| 17:15 | GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH) |
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden) |
| 17:45 | First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases |
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany) |
| 18:15 | Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other |
Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| 18:45 | Closing Remarks, EFMC-ISMC 2021 and EFMC Events |
Prof. Karl-Heinz ALTMANN (ETH ZÜRICH, Zürich, Switzerland)
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 19:00 | End of the EFMC-ISMC Virtual Event 2020 |
|
